Elysium Therapeutics, Inc.

📍 Akron, United States🗓 Founded 2013👥 6 employees💰 Last funded Oct 2020
Biotechnology🌐 elysiumrx.com
Website LinkedIn
Elysium’s mission is to reduce suffering from severe acute pain, opioid-use disorder (OUD), and fatal opioid overdose by developing first- or best-in-class products with profiles that address the key limitations and dangers associated with opioids used today. Our pipeline consists of 3 diverse platforms with broad applicability across several areas of significant unmet need: Technologies 1. O2P™ (Oral Overdose Protection) – Lead platform Traditional opioids are easy to abuse, with euphoria and risk of respiratory depression increasing with every pill consumed. O2P provides self-limiting exposure to active opioid and prevents overdose. 2. XpiRx™ (Forced Expiration) 70-year half-life of traditional opioids creates a surplus supply of readily available pills that can end up on the streets. XpiRx opioids, whose potency expires after the prescribed-use period, reduce abuse and prevent fatal overdoses. 3. SOOPR™ (Synthetic Opioid Overdose Prevention and Rescue) Existing rescue agents are too short-acting and weak against synthetic opioids, often requiring multiple doses. SOOPR lasts up to 24 hours and is more effective against synthetic opioids (e.g., fentanyl, nitazenes) than today’s standard-of-care Elysium has a highly attractive risk/reward profile: 1. High-probability of Success: In vitro and in vivo proof-of-concept data for its new chemical entities that are comprised of FDA-approved drugs 2. Capital Efficiency: Leveraging non-dilutive grant funding, ~$16M to-date 3. Platform Opportunity: Diversified portfolio of programs addressing the key underlying factors that are driving the opioid crisis and could yield multiple products within 3-5 years 4. Market: Multi-billion-dollar market potential, with weak direct pipeline competition 5. Intellectual Property: Strong protection, with issued patents in the US and internationally, including composition of matter
2
Total investors
0
Early stage
1
Mid stage
1
Late stage
2013
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Elysium Therapeutics, Inc.?
Elysium Therapeutics, Inc. has 2 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did Elysium Therapeutics, Inc. last raise funding?
The most recent investment in Elysium Therapeutics, Inc. recorded on gritt.io was in October 2020.
When was Elysium Therapeutics, Inc. founded?
Elysium Therapeutics, Inc. was founded in 2013.
What industry is Elysium Therapeutics, Inc. in?
Elysium Therapeutics, Inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Elysium Therapeutics, Inc. based?
Elysium Therapeutics, Inc. is headquartered in Akron, United States.